Futura has developed a highly efficient and proprietary delivery technology DermaSys® for the absorption of active molecules through the skin. The DermaSys® technology was originally developed by Futura for use in our topical treatment for erectile dysfunction, MED2002. DermaSys® is a versatile and bespoke technology in that it can be tailored to suit the specific active compound being used and the therapeutic indication. Such targeted delivery offers an optimised profile in terms of dose, onset time and duration of effect as well as an improved safety profile through lower systemic uptake and the reduced risk of side effects.
Futura is continuing commercial negotiations on a non exclusive basis with GlaxoSmithKline for the negotiation of distribution rights for the provision of pain relief (TPR100) using DermaSys®.
To further maximise the value of this asset, Futura has been evaluating its use with a range of compounds and is expecting to start a Phase I clinical study on a treatment for premature ejaculation (PET500). In addition Futura is assessing the use of DermaSys® in a range of other compounds.